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INTRODUCTION 
Atopic dermatitis (AD) (eczema) is a chronically relapsing inflammatory skin disease 
associated with erythema, scaly and oozing plaques on the forehead and face, neck, hands and 
flexural areas and severe pruritus (1, 2). AD affects 2-5% of the general population, with ≥10-
20% occurrences in infants and children and 1-3% in adults (3). There is a wide variation in 
the prevalence of AD in different populations of the world, and it appears to increasing (4, 5). 
Eczematous skin changes (infantile eczema) of early childhood may differ from common 
atopic dermatitis in terms of lack of family background of atopy, absence of signs of type I 
allergies, clinical course, and failure to respond promptly to topical treatment.  
Self-healing, the susceptibility to allergy, as well as the characteristic immune profile 
of lesional skin and peripheral blood are all hallmarks of AD. They together with the 2 
different types of AD, the intrinsic and extrinsic types require new definitions and 
reassessment. According to the recent findings of a search for susceptibility genes, it appears 
that nonatopic dermatitis should be considered as a distinct entity of childhood eczema. The 
affected youngsters show dry ichthyosiform and eczematous skin changes at an early age with 
absence of sensitization to common allergens (6), and 33% of them should complete clearing 
within 5 years of age.  
The optimal protocol for their management has still not been established (7). The 
diagnostic criteria recommended by the American Academy of Dermatology at the 2003 
consensus conference are currently used by many clinicians for diagnosis and treatment of 
children and adults (8-10). Moreover, the mechanisms underlying the pathogenesis of AD 
remain unclear, although numerous studies have demonstrated the integral involvement of 
immunopathology, genetic predisposition, and emotional and environmental stimuli in AD 
development and progression (8). With the intent of bringing uniformity to the diagnosis of 
AD, Hanifin and Rajka (11) proposed a number of diagnostic criteria based on their clinical 
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experience. Williams et al. (12, 13) coordinated a UK working party and refined Hanifin and 
Rajka’s criteria for AD, which were suitable for hospital and epidemiological settings. De et 
al. (14) found statistical advantage in favor of Hanifin and Rajka’s criteria (sensitivity 96.4%, 
specificity 93.75%) compared to the UK working party’s diagnostic criteria (sensitivity 
86.14%, specificity 95.83%) that reached a level of significant of <0.005. They noted that 
dermatitis in classical distribution, its chronic relapsing nature, dry skin and infra-orbital folds 
had relative values and these features were helpful in discriminating cases of AD from 
controls.  
Terminology of AD is controversial, with many different names in different countries, 
among them neurodermitis, constitutionalis atopica, and atopic eczema. Johansson et al. and 
the European Academy of Allergology and Clinical Immunology (EAACI) (15) proposed a 
new term “atopic eczema/dermatitis syndrome” (AEDS) which was divided into non-allergic 
and allergic types, the latter applying to IgE-associated allergic AEDS. They revised the 
nomenclature of AD and atopy and called only the IgE-associated forms of the diseases true 
AD (16). It is hoped that the term “eczema” will replace the current term AD.  
Several genetic analyses have identified different chromosome regions with a linkage 
to AD features: Th2 cell cytokine genes on 5q31-33, on 1q21, 3q21, 17q25 and 20p which are 
closely with some major psoriasis loci (17,18). Further genetic regions associated with AD 
features include gene polymorphisms, activator of transcription (STAT)-6, the proximal 
promoter of regulated on activation, normal T-cell expressed and secreted (RANTES), 
interleukin (IL)-4, IL-4 Rα and transforming growth factor (TGF)-ß (5, 19, 20, 21). An 
association of one region in tron 2 polymorphisms (rs 324011) with total serum IgE and a 
STAT 6 risk haplotype for elevated IgE in white adults was also proven (21). Candidate genes 
found in regions (3q21, 5q31-33 and 11q13) code for various immunomodulators, including 
costimulatory proteins (CD80 and CD86) involved in T-cell activation (3q21), IL-3, 4, 5, 11, 
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and GM-CSF (5q31-33) and beta subunit of the high affinity IgE receptors (11q13) (8). 
Finally, a genetic linkage was shown to contribute to immunologic abnormalities of AD 
pathogenesis (22). 
Immunologic background 
Skin lesions in AD result from disturbed cellular immunity, including epidermal 
Langerhans cells (LCs) with IgE receptors of high and low affinity and humoral factors 
(increased production of IgE and collaboration with Th subsets and LCs, with resultant high 
production of related cytokines). There are activated Th1 cells with increased production of 
IFNγ in acute AD skin lesions binding to keratinocytes and, consequently, inflammatory skin 
changes in the disease (22). A relative imbalance between Th1 and Th2 subsets of CD4+ T 
cells producing cytokines are indicative of prominent immune disorders in AD (22). 
Autoreactivity to human proteins in patients with AD has been postulated as a decisive 
pathogenetic factor for AD. Several investigations have looked into the question of whether 
the stress-inducible enzyme, manganese superoxide dismutase (MnSOD) of human and 
fungal origin, might act as an autoallergen in AD. Schmid-Glendermeier et al. (23) 
investigated 69 AD patients with SCORAD 27 and demonstrated that human MnSOD may 
play a role as an autoallergen in a subset of these patients, including those with nonatopic 
eczema. The authors showed that such sensitization may be induced primarily by exposure to 
environmental fungal MnSOD of Malassezia sympodialis by molecular mimicry leading to 
cross-reactivity (23).  
Genetic and environmental factors play a pivotal role in triggering AD. Research has 
focused on patterns of cytokines and chemokines reflecting a deviated immune response in 
AD and on the involvement of various cells and the epidermal barrier. The findings on T cells 
with regulatory features as well as on IgE-mediated autoreactivity will give insight into the 
defective tolerance of AD patients (24). 
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Imbalance of Th1 and Th2 in AD depends on polymorphism in the IL-18 gene on 
peripheral mononuclear cells, which reacts after stimulation with superantigens through 
upregulation of IL-18 and downregulation of IL-12 (24). Substance P, “nerve growth factor” 
(NGF) and vasoactive intestinal polypeptides (VIP) are increased in the blood of AD patients. 
Cytokines and chemokines are also key factors in the pathogenesis of AD. There is a Th2 
cytokine profile of IL-4, IL-5 and IL-13 in the skin in the acute phase of AD, while Th1/0 
with IFNγ IL-12, GM-CSF prevail in the chronic phase. Moreover, eosinophilic cationic 
protein (ECP) and IL-16 are elevated in the acute AD phase, and IL-10 plays an important 
immunoregulatory role in atopic as well as in nonatopic eczema (24). In lesional AD skin, 
there are two types of the high-affinity receptors for IgE-bearing myeloid dendritic cells (DC), 
i.e., LCs and inflammatory dendritic epidermal cells (IDECs), each of which displays a 
different function in the pathophysiology of AD (10). Specifically, LCs play a predominant 
role in the initiation of the allergic immune response and conversion of prime naïve T cells 
into the T cell of the Th2 type with high amounts of IL-4. Furthermore, stimulation of high-
affinity receptors for IgE on the surface of LCs by allergens induces the release of 
chemotactic signals and recruitment of IDECs and T cells in vitro. Stimulation of FcγRI on 
IDECs leads to the release of high amounts of proinflammatory signals, which contribute to 
allergic immune response.  
Keratinocytes play a role in innate immunity by expressing tall-like receptors and by 
producing antimicrobial peptides in response to invading microbes (25). AD keratinocytes 
secrete a unique profile of chemokines and cytokines. Apoptosis of keratinocytes is a crucial 
event in the formation of eczema (spongiosis in AD). The expression of different 
immunologic parameters have been studied in AD patients since immune dysregulation is a 
possible key defect in AD. Regulatory T cells (Tregs) or Th3 cells (CD25+/CD4+) can 
suppress Th1 as well as Th2 cells. Superantigens of S. aureus cause defects in Tregs function 
6 
 6 
 
and promote the skin inflammation (24). Autoallergens (e.g. Homs 1-5 and DSF 70) are 
atopy-related autoantigens (ARA) in the setting of AD and other atopic diseases. IgE 
autoreactivity appears very early (during first year of life) and is associated with the flares in 
AD. Adhesion molecules may play an important role in the homing of T-cell subsets into 
allergen-exposed skin of atopic individuals. High expressions of adhesion molecules, 
especially ICAM-1 and ICAM-3, E-selectin, and L-selectin, in skin lesions of AD patients 
revealed that they may play an important role in the pathogenesis of AD and may be of 
clinical relevance for the management of AD. It is important not to ignore various molecules 
expressed on LCs, such as E-cadherin, a homophilic adhesion molecule, and others (26).  
AD is product of an interaction between various susceptibility genes, host and 
environmental factors, infectious agents, defects in skin barrier function and immunological 
responses (27). Activation of T lymphocytes, DCs, macrophages, keratinocytes, mast cells 
and eosinophiles are characteristic of AD skin inflammatory responses (10). 
Histopathology 
Clinically unaffected skin in AD is still not normal. It has a greater irritant skin 
response than healthy skin with microscopically sparse perivascular T-cell infiltrate, 
eosinophiles and macrophages (26). There is marked infiltration of CD4+ activated memory T 
cell, of LCs (to a lesser extent), of IDECs, and of macrophages in lesional acute AD skin 
lesions. In chronic AD skin lesions is a chronic inflammation with increased collagen 
deposition in the dermis, and macrophages dominate in the dermal mononuclear cell infiltrate 
with eosinophils and smaller numbers of T cells (10, 26). 
IgE and IgE receptors 
Serum IgE levels are elevated in about 80% of adult AD patients, who also show 
sensitization against air-borne and food allergens and/or concomitant allergic respiratory 
allergy (10, 28). The subtype of AD with normal serum IgE levels has a late onset (>20 years 
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of age) and a lack of these sensitizations. Some of these patients, however, have IgE 
sensitization against microbial antigens (Staphylococcus aureus enterotoxins and Candida 
albicans or Malassezia sympodialis) with low IgE serum levels and without any detectable 
sensitizations. These cases develop into the extrinsic variant of AD with increasing IgE serum 
levels and sensitizations against air-borne and food allergens later in life.  
Expression of high-affinity IgE receptor (FcεRI) can be found in the epidermal skin 
lesion of patients with AD because of higher IgE-binding capacity of the DCs in their skin 
and blood (10).  
Skin barrier disfunction 
AD is characterized by dry skin and increased transepidermal water loss even in 
non-lesional skin, and fewer ceramides in the cornified envelope of lesional and non-lesional 
skin are found AD patients (10, 29). Changes in the stratum corneum pH in AD skin may 
impair lipid metabolism in the skin. Such alterations allow penetration and susceptibility of 
irritants and allergens, triggering the inflammatory response, cutaneous hyper-reactivity, 
inflammation and skin damage characteristic of AD (10). Filaggrin deficiency leads to mild or 
severe ichthyosis vulgaris and impaired keratinocytes differentiation and barrier formation 
allow increased transpidermal water loss, and entry of allergens, antigens, and chemicals from 
the environment in AD (30). 
Diagnosis 
Well-defined diagnostic criteria are important in the diagnosis of AD and diagnostic 
criteria developed by Hanifin and Rajka (11) are widely accepted. Skin biopsies are not 
essential for the diagnosis but they can exclude other diagnosis in adults. In The 
differential diagnosis, combination forms with components of atopic, contact, and irritative 
eczema are important. Atopic eczema of the hands and the feet must be differentiated from 
psoriasis, from keratodermas in the palms and soles and from tinea. The differential 
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diagnosis of acute AD with intense erythema of the skin, together with exudation or 
blistering, for example, differs from differential diagnoses of the chronic lichenified form. 
Diagnostic tests 
The investigation of exacerbating factors in AD involves a patient history, specific skin 
and blood tests, and challenge tests, depending on the degree of the disease severity and on the 
suspected factors involved. The APT was introduced to assess sensitization to inhalant 
allergens in AEDS patients. Fuiano and Incorvaia (31) recently confirmed the high value of 
APT in patients with mite-induced AEDS and suggested that its routine use might also 
improve the diagnosis of respiratory allergy to house dust mites. 
Cytokine responses to allergens can be detected in cord blood mononuclear cells 
(CBMC), suggesting allergen priming already in utero. Nilsson et al. (32) found that 53 out of 
82 patients with AEDS had significantly lower numbers of IFNγ-producing CBMC after 
stimulation with various antigens than their non-AEDS counterparts. They found a low 
number of IL-12-producing CBMC to be associated with IgE sensitization during early 
childhood and that a reduced number of IFNγ-producing CBMC promotes the development of 
AEDS during the first 2 years of life (32). 
The APT is primarily a tool for investigating the mechanisms of eczema in the skin. It 
can, however, also reveal sensitization in patients with AD and might identify a subgroup of 
AD patients (10).  
Sensitization to inhalant allergens (e.g., dust, mites, animal dander and pollen) can be 
detected by SPTs (if the skin is free from eczema) or by measuring specific IgE antibodies. 
Contact sensitization to topical medications frequently occurs in AD patients, 
especially in adults. The possibility of contact allergy needs to be ruled out by patch testing (10, 
33).  
Treatment  
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Topical 
Management of AD is a clinical challenge. Basic therapy of AD should comprise optimal 
skin care, addressing the skin barrier defect with regular use of emollients and skin 
hydration, along with identification and avoidance of specific and nonspecific trigger 
factors (10). Nonspecific irritants include contactants, such as clothing. Irritating factors 
also are soaps and hot water during showering or bathing. Mild syndets with an adjusted 
pH value (acidified to pH 5.5-6.0) should be used for cleansing. There are a number of 
therapeutic agents for use according to disease severity: basic therapy for solely dry skin, 
low-to-mid potency topical corticosteroids (TCs) and/or topical calcineurin inhibitors 
(TCIs) for mild to moderate AD, mid-high potency TCs/TCIs for moderate-to-severe AD, 
and systemic therapy (e.g. cyclosporine A or phototherapy) for recalcitrant, severe AD. A 
combination of different topical agents may be indicated. Systemic treatment options are 
recommended in cases of severe AD. 
There is severe dryness of the skin in AD because of an increased transepidermal 
water loss caused by a dysfunction of the skin barrier (10). The regular use of emollients 
is important for addressing this problem and, together with skin hydration, it represents the 
mainstay of the general management of AD. Emollients should be applied continuously, 
even if no actual inflammatory skin lesions are apparent. Emollients containing polidocanol 
are effective in reducing pruritic symptoms. Urea is used for intensive hydration of the 
skin, while salicyl acid can be added to an emollient for the treatment of chronic 
hyperkeratotic lesions.   
Topical corticosteroids (TCs) 
Topical corticosteroids have been for several decades the mainstay of AD therapy and 
other inflammatory disorders. TCs are still important in the treatment of acute flare-ups. 
Different therapeutic schemes have been established for the topical administration of TCs: 
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intermittent use may be as effective as an initial therapy with a high potent steroid followed 
by a time-dependent dose reduction or switch to a lower potent preparation. The choice of 
an adequate vehicle is important to achieve the optimal therapeutic effect. Treatment with 
TCs contributes to a reduction of skin colonization with S. aureus and may affect a further 
trigger factor of AD. Only mild-to-moderately potent preparations should be used on 
genital, facial, or intertriginous skin areas, in short-term application, and only 
mild-to-moderately potent steroid preparations should be used in children. During acute 
flares, steroids should be used in combination with emollient skin care to avoid steroid 
overuse and steroid-related side effects (10). 
Topical calcineurin inhibitors 
Topical immunomodulators are a relatively new class of medications for the 
treatment of AD.  They are effective for the treatment of AD, but are also effective in a 
number of other steroid-responsive dermatoses. Tacrolimus (Protopic) ointment is a 
topical formulation of FK506, and pimecrolimus cream (Elidel) of a new oral ascomycin 
derivate (34). Tacrolimus and pimecrolimus are selectively inhibitors of the activation of 
T Cells by inhibiting phosphatase calcineurin. After T lymphocyte activation (after 
interaction of costimulatory ligands on antigen-presenting cells with T-cell receptor) this 
increases the levels of free calcium within the cell, which binds to calmodulin and in turn 
activates calcineurin. Tacrolimus and pimecrolimus inhibit calcineurin and preventing the 
dephosphorylation activity of phosphatase and the production and release of inflammatory 
cytokines and T-cell proliferation (34).  
It is important in ADS treatment with pimecrolimus and tacrolimus according 
guidelines and recommendation to include optimal skin care, identification of triggers, 
treatment of infections and avoidance of allergens (35). FDA raised concerns about 
potential malignancy risk that can be observed with increased concerns for risk for 
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malignangy (36). Pimecrolimus and tacrolimus are steroid-free, anti-inflammatory topical 
medications for the treatment of AD. In the USA and Europe, pimecrolimus cream (1%) and 
tacrolimus ointment (0.03%) are government-approved for the treatment of AD from the age 
of 2 years, while tacrolimus ointment 0.1% is only approved in adults. The anti-inflammatory 
potency of 0.1% tacrolimus ointment is similar to a corticosteroid with moderate potency. 
Both agents proved to be effective, with a good safety profile for a treatment period of up 
to 2 years with pimecrolimus and up to 4 years with tacrolimus (10, 37). Current FDA 
guidelines recommend that topical pimecrolimus nad tacrolimus are indicated for the short-
term or intermittent-long-term treatment of AD in patients 2 years of age or older who are 
unresponsive to or intolerant of other conventional therapies or in whom there therapies are 
inadvisable because of potential cancer risk (35). 
Wet-wrap therapy 
A wet layer of cotton dressing in combination with antiseptics or topical steroids 
(TCs) has been shown to be beneficial in cases of exacerbated AD skin lesions (10, 38). 
Topical antimicrobial therapy 
Topical antiseptics, such as triclosan or chlorhexidine, offer the advantage of a low 
sensitizing potential and low resistance rate. They can be used in emollients or a supplement 
in “wet-wrap dressing” therapy. The combination of a topical antimicrobial agent to a topical 
steroid preparation has been shown to result in greater clinical improvement over a 
topical steroid alone (10). A topical antibiotic treatment might be beneficial for the 
treatment of mild and localized forms of this secondary infection. Topical fusidic acid has 
proved to be very effective against S aureus (application for periods of no longer than 
about 2 weeks is advisable). Other secondary infections caused by yeasts, dermatophytes, 
or streptococci have also been implicated as trigger factors in AD and should be treated 
(10). 
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Systemic management 
Systemic antibiotic treatment is indicated for widespread bacterial secondary infection 
(primarily S aureus). First- or second-generation cephalosporins or semisynthetic 
penicillins administered for 7-10 days are usually effective. Clindamycin or oral fusidic acid 
are possible alternatives in cases of penicillin or cephalosporin allergy. Maintenance 
antibiotic therapy, however, should be avoided since it might result in colonization by 
methicillin-resistant organisms. Infection with herpes simplex virus (Kaposi’s varicelliform 
eruption) is a severe and life-threatening complication of AD and requires a systemic 
antiviral treatment with acyclovir or other antiviral agents (e.g., valacyclovir) (10). 
Systemic corticosteroids 
In cases of acute flare-up, patients may benefit from a short course of systemic 
therapy with corticosteroids, but long-term use in adults and any use in children should 
be avoided. 
Cyclosporin A 
Cyclosporin is immunosuppressive and anti-inflammatory drug. T-cell receptor 
activation causes release of intracellular calcium that in turn binds to calmodulin and 
activates calcineurin. Calcineurin complex then dephosphorylates the nuclear factor of 
activated T-cells (NFATc) which migrate into the nucleus and make complex which is a 
transcription factor for inflammatory cytokines (e.g. IL-2). Cyclosporin binds to 
cyclophilin (intracytoplasmic proteins – immunophylin) which blocks the 
dephosphorylation of NFAT, resulting in a decrease of T-helper cells (CD4) and cytotoxic 
(CD8) in the epidermis (39). Cyclosporin A (CyA) inhibits calcineurin-dependent 
pathways, resulting in reduced levels of proinflammatory cytokines, such as IL-2 and 
IFN-g. CyA is effective in treatment for both adult and childhood AD. Because of the 
possible side effects, particularly renal toxicity, the use of CyA should be limited to patients 
13 
 13 
 
with severe refractory disease. The treatment may be administered in the form of a short- 
or long-term therapy with high-dose (3-5 mg/kg/d) or low-dose (2.5 mg/kg/d) regimens, 
depending on the individual patient’s medical condition. If after three months of the 
maximum dose of CyA (5 mg/kg/day), the therapy has failed and should be discontinued 
(39).  
Azathioprine 
Azathioprine (Imuran) is a well-known systemic immunosuppressive agent from 
1959 that affects purine nucleotide synthesis and is effective in severe recalcitrant AD 
(10). It has a number of side-effects including myelosuppression, hepatotoxicity, and 
susceptibility for infection. The recommended dosage of azathioprine for dermatologic 
indications is 1-3 mg/kg daily but it should be determined based on thiopurine 
methyltransferase levels (TPMT). Knowing the baseline TPMT activity is clinical useful in 
the majority of patients who receive azathioprine and to monitoring during the therapy 
(39). Benefits may not be apparent until 2-3 months after treatment onset. 
Antihistamines 
The therapeutic value of antihistamines seems to reside principally in their sedative 
properties, and they are useful as a short-term adjuvant to topical treatment during 
relapses associated with severe pruritus. The second generations antihistamines, cetirizine 
hydrochloride, loratadine, fexofenadine hydrochloride have distinct effect because have 
longer half-lives. Desloratadine has proven effectiveness in controlling pruritus. 
Nonsedating antihistamines seem to have only very modest value in atopic eczema. 
Leukotriene antagonists 
 Leukotriene antagonists (montelukast and zafirlukast) are useful for the treatment of 
asthma and allergic rhinitis. In AD therapy is not fully elucidated. Zafirlukast is approved  in 
AD and asthma for adolescents and  adults (5). In chronic AD montelukast achieved little 
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success. Montelukast administrated 5 mg daily for four weeks in clinical double-blind study of 
moderate to severe AD in young patients (6-16 years) showed a significant decrease in disclose 
severity, but in other study with severe AD and different doses (5 mg, 10 mg, 20 mg) there was 
partial improvement (relieve of pruritus; abatement erythema) in few patients. AD patients 
failed to show any benefit from leukotriene receptor antagonist therapy (5). 
Phototherapy 
The following therapy options may be used for AD: broad-band UVB (280-320 
nm), narrow-band UVB (311-313 nm), UVA (320-400 nm), UVA1 (340-400 nm), PUVA, 
and PUVA bath. Combinations of UVB and TCs and UVB with UVA as well as UVA1 
medium- and high-dose therapy are useful in AD therapy (40). In the pediatric population, 
UV therapy should be restricted to children above 12 years of age. 
Interferon therapy 
Interferons (IFN) are a family of secretory glycoproteins produced by most 
eukaryotic cells triggering by a variety of viral and non viral inducers. In dermatologic 
disorders there are three forms of IFN (IFN-α2a; -α2b and γ) with antiviral, antiproliferative 
and immunoregulatory clinical effects (34). Evidence of reduced production of IFN-γ in 
vitro by mononuclear cells of patients with AD, and the suppression of IL-4 mediated IgE 
stimulation by IFN-γ has prompted evaluation of the use of IFN in AD. In randomised 
placebo-controlled double blind multicenter trial studies the effects of daily Sc injection (50 
µg/m2) recombined IFN-γ achieved in 45% - 57% (10-100 µg/m2) a significant clinical 
response (34). Therapy with IFN-α has been investigated in patients with AD with varied 
and contradictory results (34).  
Bioengineered immunomodulators  
Most of the new approaches aim at inhibiting components of the allergic 
inflammatory response, including cytokine modulation (e.g., TNF inhibitors), blockade of 
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inflammatory cell recruitment (chemokine receptor antagonists, CLA inhibitors), and 
inhibition of T-cell activation (alefacept and efalizumab) (10). For AD treatment 
bioengineered immunomodulators are in clinical trial phase. Agent that interfere with T-cell 
activation or T-cell trafficking in the skin (alefacept, efalizumab)  are effective in the 
treatment of psoriasis. They changing the immune profile from Th1 to Th2, or blocking 
cytokines but this agents are currently in clinical trials for psoriasis and psoriatic arthritis. 
Infliximab (Remicade) is a chimeric (human-mouse) monoclonal antibody and its target is 
human TNF-α. Infliximab binds to soluble forms of TNF-α and blocks the interaction of 
TNF-α with TNF-α receptors. Inliximab is aproved  for the treatment of Crohn’s disease 
and rheumatoid arthritis, pioderma gangrenosum and psoriasis (34). 
 
IgE- blocking antibody 
 IgE-blocking antibody omalizumab (Xolair) is recombinant human monoclonal 
antibody which is target and specific antihuman IgE drug (binds free serum IgE and avoid 
the binding to FcεRI-receptor as well as FcεRII (CD23) receptor on mast cells, basophyles 
and antigen presenting cells surface which stops releasing of proinflammatory mediators). 
Xolair is administrating for adults and children older than 12 years with asthma and AD 
for three months; than s.c. injections of 0,015 mg/kg IgE and 0,03 mg/kg each two weeks or 
four weeks. Before the therapy and three months later the down-regulation of IgE receptors 
is needed. Omalizumab role in dermatology and for AD is probably best directed toward 
patients with high levels of IgE in whome the IgE is an etiologic factor for their disease 
(41). 
Conclusion 
In AD complex and genetically determined aethiopathophysiology there has been 
major progress in the last decade, but there is no complete cure for AD. Much more clinical 
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research is needed for therapeutic approach of AD recommended. Patients education 
programs should be the active part in the management of AD. Management currently focuses 
on avoidance of triggers, skin hydration and reduction of skin inflammation and AD disease 
control and prevention of flair.   
Summary 
We described atopic eczema/dermatitis from the aspects of immunologic background, 
genetics, skin barrier dysfunction, IgE receptors, and triggers of AD (including allergens, 
microorganisms, and autoantigens). We have also reviewed diagnostic procedures, treatment 
modalities with topical treatment (emollients, topical corticosteroids, topical calcineurin 
inhibitors, wet wrap therapy and topical antimicrobial therapy) as well as systemic 
management (antimicrobials, systemic corticosteroids, cyclosporine A, azathioprine, 
antihistamines) and phototherapy. Finally, we have discussed primary and secondary 
prevention and have emphasized the role of the different cell receptors and their up- and 
down-regulation in this setting. 
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